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Abstract
Introduction: Infective endocarditis (IE) and other severe infections induce significant changes in the immune response in a
considerable number of affected patients. Numerous IE patients develop a persistent functional immunological phenotype that can
best be characterized by a profound anti-inflammation and/ or functional “anergy.” This is pronounced in patients with unresolved
infectious foci and was previously referred to as “injury-associated immunosuppression” (IAI). IAI can be assessed by measurement
of the monocytic human leukocyte antigen-DR (mHLA-DR) expression, a global functional marker of immune competence.
Persistence of IAI is associated with prolonged intensive care unit length of stay, increased secondary infection rates, and death.
Immunomodulation to reverse IAI was shown beneficial in early immunostimulatory (randomized controlled) clinical trials.
Methods: Prospective 1:1 randomized controlled clinical study to compare the course of mHLA-DR in patients scheduled for
cardiac surgery for IE. Patients will receive either best standard of care plus cytokine adsorption during surgery while on
cardiopulmonary bypass (protocol A) versus best standard of care alone, that is, surgery without cytokine adsorption (protocol B). A
total of 54 patients will be recruited and randomized. The primary endpoint is a change in quantitative expression of mHLA-DR
(antibodies per cell on CD14+ monocytes/ macrophages, assessed using a quantitative standardized assay) from baseline
(preoperation [pre-OP], visit 1) to day 1 post-OP (visit 4).
Discussion: This randomized controlled clinical trial (RECReATE) will compare 2 clinical treatment protocols and will investigate
whether cytokine adsorption restores monocytic immune competence (reflected by increasedmHLA-DR expression) in patients with
IE undergoing cardiac surgery.
Trial registration: This protocol was registered in ClinicalTrials.gov, under number NCT03892174, first listed on March 27, 2019.
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Abbreviations: AUC = area under the curve, CE = European Conformity, ECMO = extracorporeal membrane oxygenation, IAI =
injury-associated immunosuppression, ICH = International Council for Harmonization of Technical Requirements for
Pharmaceuticals for Human Use, ICU = intensive care unit, IE = infective endocarditis, IL = interleukin, mAb/cell = monoclonal
antibodies per cell, mHLA-DR =monocytic human leukocyte antigen – DR isotype, OP = operation, TISS = Therapeutic Intervention
Scoring System.
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1. Introduction
Infective endocarditis (IE) is a life-threatening clinical condition
that is characterized by infection of the endo-(myo)cardium and
cardiac valves.[1] IE treatment depends on the severity of the
infection and induced tissue damage. As first-line clinical therapy,
systemic intravenous antibiotic treatment according to interna-
tional guidelines is applied.[1,2] In severe IE affecting the function
of heart valves, surgical repair and replacement can be deemed
necessary. The decision when to operate on a patient is based on
internationally approved guidelines[2] and depends on expected
or observed complications, severity of valve dysfunction, and size
of vegetation(s).[1] The aim of surgery is to control the site of
infection and to restore (normal) heart functionwhile repairing or
replacing the infected valve and to repair associated defects
(abscess). During cardiac surgery itself, the use of a cardiopul-
monary bypass circuit is required.
Severe infections, such as IE, are known to induce significant
changes in a hosts’ immune response.[3–7] In fact, numerous
patients with IE develop a persistent functional immunological
phenotype that can best be characterized by a profound anti-
inflammation and functional immunological anergy.[3,5,8] This
seems especially the case in patients with unresolved infectious
foci and was previously referred to as “injury-associated
immunosuppression” (IAI).[3] IAI can be assessed by measure-
ment of the monocytic human leukocyte antigen-DR (mHLA-
DR) expression, a standardized “global” biomarker of immune
competence.[8,9] Persistence of IAI is associated with prolonged
intensive care unit (ICU) length of stay, increased secondary
infection rates, and death.[3]
Immunomodulatory therapies aiming to reverse IAI and were
shown beneficial in early clinical trials.[10,11] Recent expert panels
suggest evaluation of clinical immunomodulatory strategies,
including extracorporeal approaches.[4] We could previously
show that assessment of the surface expression of HLA-DR on
monocytes/macrophages correlates with the functional status of
the cellular immune system in critical illness and may be regarded
as a global marker of cellular immune function in ICU
patients.[3,10,11] An intervention to reduce immune mediators
may affect the net dysregulated immunological response,[11] that
is, to restore functional immunocompetency. Via comparison of 2
clinical protocols (i.e., cardiopulmonary bypass with cytokine
adsorption plus best standard of care vs best standard of care
alone), we will investigate whether adsorption modulates
functional cellular immunocompetence,[9] which was shown of
prognostic importance in the postoperative course of respective
patients.[3] Cytokine adsorption will be performed during
cardiopulmonary bypass with a European Conformity (CE)-
marked medical device approved for this indication. Studies have
confirmed the safety of this device, but no data on direct
immunological effects (i.e., change in net immune status) are
available.[11–17]
We therefore embarked to investigate in a 1:1 randomized
controlled clinical trial whether intraoperative cytokine adsorp-
tion would improve mHLA-DR expression and thus immune
competence.
2. Methods
2.1. Type of study
Cytokine REmoval in CRitically ill pAtients requiring surgical
Therapy for infectiveEndocarditis (RECReATE) is an investigator-
initiated, prospective, single-center randomized controlled clinical
trial. Sponsor is Prof. Lars Englberger from the Department of
Cardiovascular Surgery of Inselspital, Bern University Hospital.
Cytokine adsorption will be performed using a CytoSorb
adsorption device (Cytosorb GmbH, Berlin, Germany), a CE-
markedandapprovedmedical device for treatmentof patientswith
IE undergoing cardiac surgery. Cytokine adsorption will be
employed during surgery for IE on cardiopulmonary bypass only.
The study is performed in a tertiary care academic center
(University of Bern, Inselspital, Bern, Switzerland) at the Depart-
ments of IntensiveCareMedicine,Cardiovascular Surgery, and the
Department of Anaesthesiology and Pain Medicine. Recruitment
started in November 2019 (ongoing) and the actual protocol
version is V1.2, dated August 8, 2019.
2.2. Approvals/trial registration
This study was approved by the respective competent local ethics
committee on human research (Kantonale Ethikkomission, Bern,
Switzerland, approval number 201901038). Informed consent
will be achieved from all participants/legal representatives. This
protocol was registered on March 27, 2019 at clinicaltrials.gov
(NCT03892174) before study start. The study is carried out in
accordance with the protocol and principles enunciated in the
current version of the Declaration of Helsinki, the guidelines of
Good Clinical Practice issued by International Council for
Harmonization of Technical Requirements for Pharmaceuticals
for Human Use (ICH). Results will be published in a peer-
reviewed journal and disseminated at international conferences.
2.3. Study design
This study is a prospective 1:1 randomized single-blinded (subject
blinded) controlled clinical trial including IE patients scheduled for
surgery. All patients scheduled for cardiac surgery due to IE are
screened for potential study inclusion. Patients willing to participate
after having been fully informed about the study by a cardiac
surgeonwill have to signwritten informed consent.Anypatientwho
discontinues the study will be replaced. Study procedures are
performed according to the planned time schedule in adherence to
visit intervals indicated given in the SPIRIT diagram (Table 1).
2.4. Population and sample size calculation
Fifty-four patients undergoing planned surgical treatment for IE
will be randomly allocated (1:1 allocation) to receive either best
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standard of care plus cytokine adsorption (protocol A) or best
standard of care alone (protocol B). Allocation to the groups,
protocol A or protocol B, is done computerized using the
REDCap software. The null hypothesis is that there is no
differences in mHLA-DR expression (readout: monoclonal
antibodies [mAb/cell]) between the 2 groups. Assuming the
response to be normally distributed within each subject group
with a standard deviation of 3200mAb/cell and a true difference
in the arms means of 2500mAb/cell (10,000 vs 7500mAb/cell of
mHLA-DR expression), n=27 patients will be required to be able
to reject the null hypothesis that the population means of the
experimental and control groups are equal with probability
(power) of 0.8. The type I error probability associated with this
test of this null hypothesis is 0.05 (2 sided).
The following inclusion criteria apply:
1. Subjects scheduled for cardiac surgery for infectious endocar-
ditis (according to DUKE criteria) with antibiotic therapy for
14 days.
2. Presence of informed consent
3. Age ≥18 years.
The following exclusion criteria apply:
1. Known previous treatment (last 6 months) with immunologi-
cally active biologicals or specific immunomodulatory drugs
(e.g., rituximab).
2. Known high-dose chronic (i.e., before onset of infectious
endocarditis) steroidmedicationwith prednisone equivalent of
>30mg/day.
3. Patients on extracorporeal membrane oxygenation (ECMO),
or any other (preoperative) cardiac assist device.
4. Moribund patient (life expectancy <14 days, as judged by
investigator).
2.5. Outcome measures
2.5.1. Objectives. The purpose of this study is to compare
2 clinical protocols and to investigate whether cytokine
adsorption during surgery can modulate the function of
monocyte/macrophages, which are key immune cells in patients
with severe infections. Monocytic immune competence is
assessed by standardized quantitative flow cytometric measure-
ment of mHLA-DR (BD Quantibrite-HLA-DR/Monocyte-BD
Biosciences).
2.5.2. Primary endpoint.
1. Change in quantitative expression of mHLA-DR (given in
antibodies per cell [Ab/cell] on CD14+ monocytes/ macro-
phages, assessed using a standardized quantitative assay)
from baseline (preoperation [pre-OP], visit 1) to day 1 post-
OP (visit 4).
2.5.3. Secondary endpoints.
1. Change in mHLA-DR from baseline (pre-OP) to post-OP
(visit 4) and day 3 (visit 5) post-OP.
2. Area under the curve (AUC) of quantitative mHLA-DR
expression between baseline (pre-OP), ICU admission, and
days 1 (visit 4) and 3 (visit 5) post-OP.
Table 1
SPIRIT figure indicating visits/study-specific assessments.
Study periods Screening Follow-up
Visit 1
pre-OP
(Baseline)
2
OP
3
ICU admission
4
Post-OP day 1
(ICU/IMC)
5
Post-OP day 3
(ICU/IMC)
6
Follow-up
Time, day 0 0/1 (OP) ICU admission First morning post-OP Third morning post-OP 90 Days post-OP
In-/exclusion criteria x
Informed consent x
Randomization x
Demographics/history x
OR data (incl. treatment times) x
Clinical scores (disease severity):
SOFA, SAPS II, TISS 28
x X x
Lab markers: organ dysfunction
and inflammatory markers,
including CRP, PCT,
leukocyte, and platelet counts
(if available)
x x X x
Study-specific blood sampling:
flow cytometry, inflammatory
mediators
x x X x
20.5mL EDTA blood for
biobanking
x x X x
Outcomes: ICU mortality, hospital
mortality, 28-day mortality,
90-day mortality. Length of
ICU stay, length of hospital
stay
(x) (x) (x) (x) X
CRP = C-reactive protein, EDTA = Ethylenediaminetetraacetic acid, ICU = intensive care unit, IMC = intermediate care unit, OP = operation, PCT = Procalcitonin, SAPS II = Simplified Acute Physiology Score II,
SOFA = Sequential Organ Failure Assessment, TISS = Therapeutic Intervention Scoring System.
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3. Change in inflammatory markers including cytokines
(including white blood count, C-reactive protein, interleukin
6 [IL-6], IL-10, multiplex enzyme-linked immunosorbent
assay, inflammatory markers) and immune cell phenotype
(flow cytometry) from pre-OP to days 1 (visit 4) and 3 (visit 5)
post-OP.
4. Change in organ dysfunction (Sequential Organ Failure
Assessment scores including subscores) from baseline (pre-
OP) to days 1 (visit 4) and 3 (visit 5) post-OP.
5. Length of ICU/hospital stay (days after ICU admission) and
total days in hospital.
6. Cumulative Therapeutic Intervention Scoring System (TISS)
points (resource need) while on ICU.
7. ICU-, hospital-, 28-day, 60-day, and 90-day mortality.
8. Total amount of infused fluids on ICU; including number and
type of transfusions.
9. Duration of vasoactive drug therapy, cum. vasopressor dose.
10. Length of invasive mechanical ventilation (intubation to
extubation), renal function (secondary) ECMO, or other
circulatory supporting systems.
2.6. Trial monitoring
Trial monitoring is performed according to monitoring plan V
1.0, dated October 31, 2019. The study will be monitored by a
trained monitor including 100% of informed consent and
inclusion and exclusion criteria data, as well as monitoring of
100% of source data regarding the primary endpoint. Monitor-
ing of trial data and documentation will ensure that protocol
requirements, applicable local laws, ICH guidelines, and
investigator obligations are fulfilled.
2.7. Study-specific analysis and clinical measures
Blood samples for investigating functional cellular immunity,
inflammatory response patterns, and course of organ (dys)
function will be drawn preoperatively at baseline (visit 1), at ICU
admission (visit 3), on postoperative day 1 (visit 4), and on
postoperative day 3 (visit 5). In addition, blood samples will be
stored for Biobanking (Liquid Biobank Bern). In addition, several
clinical outcome parameters, and changes in organ dysfunction
and necessity of organ support, will be followed up during
hospital stay (Table 1). The primary outcome is measured by flow
cytometry using a standardized mHLA-DR assay, as outlined
above. ELISAmeasurements (CubeDx, St. Valentin, Austria) will
be performed using a multiplex ELISA technique. In addition,
routine clinical and laboratory data (if available) are used to
evaluate and/or to follow-up organ (dys)function(s), inflamma-
tion, and/or hemodynamics.Mortality (ICU, hospital, and during
follow-up) is evaluated using hospital records, official registries,
or other information.
2.8. Analysis of results
The primary analysis will be performed on the full data set, that
is, the intention-to-treat population. In an additional per-
protocol analysis, we will exclude patients with major protocol
deviations or missing primary outcome data.
We will apply a linear model corrected for the baseline value to
analyze the mean change in quantitative expression of mHLA-
DR (mAb/cell on CD14+ monocytes/macrophages) in patients
treated with protocol A versus protocol B, namely the following
quantity: YA XA  YB XB
 
, with XA;YA being the proto-
col A quantitative expression of mHLA-DR at times 1 and 3
respectively and XB;YB being the protocol B quantitative
expression of mHLA-DR at times 1 and 3, respectively, and
YA XA; YB XB
 
being paired averages. We will assess the
normality of model residuals and if the approximate normality is
not satisfied wewill use transformations ofYij andXij (with log or
Box-Cox transformations). In case we do not achieve normality
with any transformation we will use the Wilcoxon-Mann-
Whitney test for comparing distributions of YiA XiA and
YiB XiB.
We will assess the AUC for the quantitative expression of
mHLA-DR over time by computing the surfaces under the
trajectories of quantitative expression of mHLA-DR and abscissa
axis per subject, compute the averages per protocol group, and
compare these averages either with an unpaired t test (eventually
with transformations for normality) or a nonparametric
Wilcoxon-Mann-Whitney test.
We will compare the average protocol trajectories of the
quantitative expression of mHLA-DR, inflammatory markers,
and organ dysfunction by fitting the following mixed-effects
model: Yijt ¼ g0 þ g1Gij þ g2Xij þ g3Tit þ g4GijTit þ ai þ eijt
(baseline value is added as a covariate) with i being the subject;
j the protocol; t the time-point 2, 3, or 4; Gij the protocol
corresponding to subject i; Xij is the quantitative expression of
mHLA-DR at time 1; Tit the time-point 2, 3, or 4 for subject i, eijt
residuals, and ai random effect capturing the individual
variability of subject i. Testing the hypothesis g4=0 is equivalent
to testing the protocol effect over time under assumption of good
model fit.
Wewill provide descriptive statistics for, for example, length of
ICU and hospital stay (days after surgical interventions), and
cumulative TISS points (resource need) and compare groups by
the nonparametric Wilcoxon-Mann-Whitney test. We will show
proportions of ICU mortality, hospital mortality, and 28-day
mortality and compare groups calculating a risk difference and
applying a chi-square test.
3. Discussion
Previous data show that functional impairment of cell-mediated
immunity reflects an additional “organ” dysfunction in the
context of life-threatening injury, such as severe infection.[3,5,17]
Although large-scale clinical data are missing, IE is known to
trigger several humoral and immune cellular pathways, often
resulting in a state of immunosuppression in affected individuals,
and this was shown of prognostic importance in critically ill
patients.[3,18]
In the current investigator-driven clinical study RECReATE,
we aim to analyze the impact of a cytokine removal strategy (1
treatment session during cardiopulmonary bypass) on key
humoral and cellular immune response mechanisms. In brief,
we strive to explore whether cytokine adsorption can increase (or
even restore) monocytic immune competence (assessed by
mHLA-DR expression) in surgically treated patients with IE.
Data from previous clinical studies investigating immunostimu-
latory[10] and selective extracorporeal cytokine removal strate-
gies[11] demonstrate that monocytic function (mHLA-DR-
expression) can be restored using comparable measures. Thus,
it seems likely that treatment using this alternative cytokine
removal strategy will result in increased mHLA-DR expression,
reflecting improved monocytic immune function.
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Our study has a number of limitations that deserve
discussion. First, this is a single-center pilot study with
inherent limitations (including limited external validity) set by
the chosen study design. Findings in this pilot study should
therefore be confirmed in subsequent multicentre investiga-
tions. Importantly, however, the primary endpoint is assessed
using a standardized quantitative assay with an adequate
inter- (and intra-) coefficient of variation shown in multina-
tional comparison studies.[8] Second, although the sample size
appears rather limited in this pilot study, it might be
considered a strength of the current analysis that the sample
size calculation/ power regarding the primary endpoint was
partly based on data from respective previous clinical studies.
Third, optimal “dose” of the cytokine adsorption applied is
currently unknown and, theoretically, one might speculate
that the applied “adsorption dose” (treatment only while
patients are on cardiopulmonary bypass) might be insufficient.
However, this best reflects current practice, in which
physicians might chose to prescribe cytokine adsorption
based on personal preference.
In conclusion, this pilot trial will answer the important
question of whether cytokine adsorption during cardiopulmo-
nary bypass will result in increased mHLA-DR expression, a
recognized global functional immune marker. Novel therapeutic
approaches seem urgently required in critically ill patients and
data from this pilot study will allow to explore new innovative
immunomodulatory strategies.
Acknowledgments
The authors thank all trial physicians, nurses, research nurses,
data managers, laboratory staff, and statistical staff for their
dedicated support of RECReATE study.
Author contributions
FG, TS, CAP, and JCS developed the research strategy, initiated
the study, drafted and finalized the protocol/ manuscript, applied
for EC approval, and supervised the trial. GE, MML, ASM, HJ,
and LE helped to draft the manuscript, performed study
assessments, recruited patients, and revised the manuscript for
important intellectual content. All authors read and approved the
final version of the manuscript.
Thibaud Spinetti orcid: 0000-0001-8057-3746.
Joerg C. Schefold orcid: 0000-0001-9162-5724.
Markus Luedi orcid: 0000-0002-9049-2584.
Gabor Erdoes orcid: 0000-0002-6742-1016.
Carmen A. Pfortmueller orcid: 0000-0003-0326-2770.
Anna S. Messmer orcid: 0000-0002-3206-9112.
References
[1] Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016;387:882–
93.
[2] Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the
management of infective endocarditis: The Task Force for the
Management of Infective Endocarditis of the European Society of
Cardiology (ESC). Endorsed by: European Association for Cardio-
Thoracic Surgery (EACTS), the European Association of Nuclear
Medicine (EANM). Eur Heart J 2015;36:3075–128.
[3] Pfortmueller CA, Meisel C, Fux M, et al. Assessment of immune organ
dysfunction in critical illness: utility of innate immune response markers.
Intensive Care Med Exp 2017;5:49.
[4] Rubio I, Osuchowski MF, Shankar-Hari M, et al. Current gaps in sepsis
immunology: new opportunities for translational research. Lancet Infect
Dis 2019;19:e422–36.
[5] Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppres-
sion: from cellular dysfunctions to immunotherapy. Nat Rev Immunol
2013;13:862–74.
[6] Schefold JC, Hasper D, Reinke P, et al. Consider delayed immunosup-
pression into the concept of sepsis. Crit Care Med 2008;36:3118.
[7] Schefold JC, Hasper D, Volk HD, et al. Sepsis: time has come to focus on
the later stages. Med Hypotheses 2008;71:203–8.
[8] Docke WD, Hoflich C, Davis KA, et al. Monitoring temporary
immunodepression by flow cytometric measurement of monocytic
HLA-DR expression: a multicenter standardized study. Clin Chem
2005;51:2341–7.
[9] Schefold JC. Measurement of monocytic HLA-DR (mHLA-DR)
expression in patients with severe sepsis and septic shock: assessment
of immune organ failure. Intensive Care Med 2010;36:1810–2.
[10] Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage
colony-stimulating factor to reverse sepsis-associated immunosuppres-
sion: a double-blind, randomized, placebo-controlled multicenter trial.
Am J Respir Crit Care Med 2009;180:640–8.
[11] Schefold JC, von Haehling S, Corsepius M, et al. A novel selective
extracorporeal intervention in sepsis: immunoadsorption of endotoxin,
interleukin 6, and complement-activating product 5a. Shock
2007;28:418–25.
[12] Ankawi G, Neri M, Zhang J, et al. Extracorporeal techniques for the
treatment of critically ill patients with sepsis beyond conventional blood
purification therapy: the promises and the pitfalls. Crit Care
2018;22:262.
[13] Baumann A, Buchwald D, Annecke T, et al. RECCAS - REmoval of
Cytokines during CArdiac Surgery: study protocol for a randomised
controlled trial. Trials 2016;17:137.
[14] Bernardi MH, Rinoesl H, Dragosits K, et al. Effect of hemoadsorption
during cardiopulmonary bypass surgery: a blinded, randomized,
controlled pilot study using a novel adsorbent. Crit Care 2016;20:96.
[15] Bonavia A, Groff A, Karamchandani K, et al. Clinical utility of
extracorporeal cytokine hemoadsorption therapy: a literature review.
Blood Purif 2018;46:337–49.
[16] Poli EC, Rimmele T, Schneider AG. Hemoadsorption with CytoSorb
((R)). Intensive Care Med 2019;45:236–9.
[17] Trager K, Skrabal C, Fischer G, et al. Hemoadsorption treatment of
patients with acute infective endocarditis during surgery with cardiopul-
monary bypass: a case series. Int J Artif Organs 2017;40:240–9.
[18] Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human
leukocyte antigen-DR expression predicts mortality in septic shock.
Intensive Care Med 2006;32:1175–83.
Gisler et al. Medicine (2020) 99:15 www.md-journal.com
5
